Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a non-peptide antagonist of the platelet surface receptor GP IIb/IIIa, preventing its binding with fibrinogen and blocking platelet aggregation.
Indicated in the prevention of myocardial infarction in acute coronary syndromes and in early percutaneous coronary intervention (PCI).
Administration by intravenous infusion for a maximum of 4-5 days.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and short half-life) make it unlikely that it will pass into breast milk in a clinically significant quantity.
The risk can be minimized by waiting to breastfeed again between 6 and 8 hours after the last administration of the medicine.
The limitation to breastfeed will depend on the clinical situation of the mother.